Epidermolysis Bullosa Dystrophica
19
5
7
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
10.5%
2 terminated out of 19 trials
77.8%
-8.7% vs benchmark
5%
1 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (19)
Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa
Rigosertib for RDEB-SCC
Artificial Intelligence Patient App for RDEB SCCs
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro
CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
Computational Drug Repurposing for All EBS Cases
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
Growth Hormone in EB
The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Proof of Concept Study for a Dressing Glove
Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer
Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa
Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)
Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)